jennifer van grol

project leader, organizational metrics and effectiveness

About

Project Leader, R&D Strategy & Operations at Alcon, a Novartis company ... April 2014 – Present (2 years 8 months)Dallas/Fort Worth Area ... day benchwork in the lab as well as coordinating new experimental avenues for the lab to undertake.

Country

united states

City

dallas

Industry

pharmaceuticals

Skill

team leadership, strategic planning, animal models, clinical development, cell culture, elisa, inflammation, ophthalmology, pharmaceutical industry, in vitro, pharmacology, biologics, immunology, cell biology, in vivo, ocular disease, drug development, drug discovery, uveitis, assay development, biochemistry, flow cytometry, cell, biotechnology, western blotting, data analysis, life sciences

Experience

pharmaceutical project manager

alcon, a novartis company

2013-6 - 2014-4 · 11 mos

Developed and managed operational execution of pharmaceutical development projects. Led cross functional teams in advancement of projects from preclinical development to global regulatory approval and launch.

senior scientist ii

novartis institutes for biomedical research (nibr)

2011-6 - 2013-6 · 2 yrs 1 mo

Develop and manage strategic direction of the ocular inflammation preclinical research group for the Ophthalmology disease area. Lead team of scientists in the identification and evaluation of experimental therapies (small molecular or biologics) for the treatment of ocular inflammation.

post-baccalaureate fellow

national institutes of health

2004-6 - 2006-7 · 2 yrs 2 mos

Performed cardiovascular development research.

project leader, organizational metrics and effectiveness

alcon, a novartis company

2014-4 - Present · 12 yrs 6 mos

Alcon, the second largest division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people's lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, wehave become the world's leading eye care company through a combination of innovative research anddevelopment, strategic acquisitions, and partnerships with renowned third-party organizations. Today,we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180markets and employing more than 24,000 people.Our three businesses – surgical, pharmaceutical and vision care – offer the widest spectrum of industryleading products that address the full life cycle of eye care needs. We treat all parts of the eye through acomprehensive line of high-quality ophthalmic surgical and pharmaceutical products, and a broadportfolio of contact lenses and lens care products.